Nintedanib Eg (Eurogenerics)

Nintedanib, the active ingredient in Nintedanib Eg, is a tyrosine kinase inhibitor presented as an oral formulation for prescription use. It is indicated for the treatment of fibrotic lung disorders, specifically idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease, in adult patients.

GNH USA supplies Nintedanib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Nintedanib is used in fibrotic lung disease pathways to limit disease progression and preserve lung function.

Idiopathic pulmonary fibrosis: slows the rate of forced vital capacity decline, helping maintain breathing capacity and quality of life in affected adults. Systemic sclerosis‑associated interstitial lung disease: reduces progression of lung fibrosis, supporting better pulmonary outcomes and functional status in patients with systemic sclerosis. Progressive fibrosing interstitial lung disease: in adults with a progressive fibrotic phenotype, it helps to slow lung function decline when conventional treatment options are limited.

Nintedanib may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Diarrhea - Nausea - Vomiting - Decreased appetite

Serious or Rare Side Effects: - Elevated liver enzymes or hepatic injury - Increased risk of bleeding events - Gastrointestinal perforation

When prescribing Nintedanib, clinicians should consider several safety measures. - Dose adjustment: renal or hepatic impairment may require dose modification. - Bleeding risk: avoid concomitant anticoagulants unless medically necessary. - Liver monitoring: perform baseline and periodic liver function tests. - Gastrointestinal events: monitor for severe diarrhea and dehydration. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Nintedanib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (warfarin, direct oral anticoagulants): heightened bleeding risk. - Antiplatelet agents (aspirin, clopidogrel): increased hemorrhage potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise drug levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - P‑gp inhibitors (e.g., verapamil): may increase exposure.